(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
A phase 2 trial of Bezuclastinib in systemic mastocytosis, run by Cogent Biosciences, Inc., now recruiting.
Overview
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis is a phase 2 interventional study registered as NCT04996875 by Cogent Biosciences, Inc., with 140 participants planned, started 2021-11-09 and due to reach its primary completion in 2025-09-19. Interventions recorded: bezuclastinib. Conditions listed: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- Trial(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Shares Bezuclastinib, Cogent Biosciences, Systemic mastocytosis.
- Trial(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Shares Bezuclastinib, Cogent Biosciences.
- TargetKIT
Shares Bezuclastinib, Cogent Biosciences, Systemic mastocytosis.
- CancerGastrointestinal stromal tumour (GIST)
Shares Bezuclastinib, Systemic mastocytosis.